Two Sigma Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-298,300
| Closed | -$659K | – | 2641 |
|
|
2023
Q2 | $659K | Buy |
298,300
+25,000
| +9% | +$51.8K | ﹤0.01% | 1704 |
|
|
2023
Q1 | $694K | Sell |
273,300
-85,700
| -24% | -$169K | ﹤0.01% | 1806 |
|
|
2022
Q4 | $671K | Sell |
359,000
-82,500
| -19% | -$206K | ﹤0.01% | 1758 |
|
|
2022
Q3 | $1.14M | Buy |
441,500
+282,700
| +178% | +$703K | ﹤0.01% | 1460 |
|
|
2022
Q2 | $306K | Sell |
158,800
-56,300
| -26% | -$123K | ﹤0.01% | 2115 |
|
|
2022
Q1 | $639K | Sell |
215,100
-100,600
| -32% | -$378K | ﹤0.01% | 1864 |
|
|
2021
Q4 | $1.42M | Sell |
315,700
-39,700
| -11% | -$188K | ﹤0.01% | 1364 |
|
|
2021
Q3 | $1.73M | Sell |
355,400
-166,600
| -32% | -$918K | ﹤0.01% | 1338 |
|
|
2021
Q2 | $3.56M | Buy |
522,000
+1,300
| +0.2% | +$10.5K | 0.01% | 1023 |
|
|
2021
Q1 | $3.68M | Buy |
520,700
+151,700
| +41% | +$1.09M | 0.01% | 987 |
|
|
2020
Q4 | $2.31M | Buy |
369,000
+312,200
| +550% | +$1.84M | 0.01% | 1183 |
|
|
2020
Q3 | $307K | Buy |
56,800
+36,200
| +176% | +$179K | ﹤0.01% | 1997 |
|
|
2020
Q2 | $108K | Buy |
+20,600
| New | +$91.5K | ﹤0.01% | 2348 |
|
|
2014
Q1 | – | Sell |
-1,033
| Closed | -$41K | – | 2599 |
|
|
2013
Q4 | $41K | Buy |
+1,033
| New | +$43.9K | ﹤0.01% | 2245 |
|
Two Sigma Advisers's PRTK Position: Q3 2023 in Review
Two Sigma Advisers sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 298,300 shares — an estimated $659K sold.
Two Sigma Advisers first reported a position in PRTK in Q4 2013 and held it in 14 quarters. The position peaked at $3.68M in Q1 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Two Sigma Advisers reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Two Sigma Advisers sold 298,300 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $659K.
- Two Sigma Advisers first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2013 and held it in 14 quarters.
- Two Sigma Advisers's Paratek Pharmaceuticals, Inc. position peaked at $3.68M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.